[{"data":1,"prerenderedAt":149},["ShallowReactive",2],{"drug-vildagliptin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":58,"warnings":68,"renal":76,"monitoring":77,"interactions":78,"review":79,"examples":82,"atc":88,"iran":90,"links":106,"populations":116},"vildagliptin",1,{"fa":7,"en":8},"ویلداگلیپتین","Vildagliptin","alimentary-metabolism",{"fa":11,"en":12},"مهارکننده DPP-4","DPP-4 inhibitor",[14],{"name":15,"market":16},"Galvus","UK",[18,19,7],"galvus","گالووس",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",false,[16],[32],{"source":33,"section":34},"uk-galvus","4.2",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":49,"notes":51},"std","type-2-diabetes",{"fa":40,"en":41},"دیابت نوع ۲ — ۵۰ mg دو بار در روز (با سولفونیل‌اوره: ۵۰ mg صبح)","Type 2 diabetes — 50 mg twice daily (with a sulphonylurea: 50 mg in the morning)",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":27,"dosesPerDay":48},2,[50],{"source":33,"section":34},[52],{"text":53,"refs":56},{"fa":54,"en":55},"بیش از ۱۰۰ mg در روز توصیه نمی‌شود. در ترکیب دوگانه با سولفونیل‌اوره ۵۰ mg یک بار صبح کافی است.","Doses above 100 mg\u002Fday not recommended. In dual combination with a sulphonylurea, 50 mg once in the morning.",[57],{"source":33,"section":34},[59],{"id":60,"severity":61,"text":62,"refs":65},"hyper","block",{"fa":63,"en":64},"حساسیت به ویلداگلیپتین.","Hypersensitivity to vildagliptin.",[66],{"source":33,"section":67},"4.3",[69],{"text":70,"refs":73},{"fa":71,"en":72},"در نارسایی کبد یا ALT\u002FAST بیش از ۳ برابر مصرف نشود؛ پایش آنزیم‌های کبد.","Not for hepatic impairment or ALT\u002FAST >3× ULN; monitor liver enzymes.",[74],{"source":33,"section":75},"4.4",[],[],[],{"status":80,"reviewer":81,"date":81},"unverified",null,[83],{"regimen":37,"formulation":22,"input":84,"expect":87},{"ageYears":85,"weightKg":86},55,80,{"perDose":27,"tabletsPerDoseRounded":5},[89],"A10BH02",{"status":91,"forms":92,"refs":101},"registered",[93,97],{"code":94,"en":95,"fa":96},"14688","INOSINE ACEDOBEN 500MG TAB","قرص اینوسین آسدوبن ۵۰۰ میلی‌گرم",{"code":98,"en":99,"fa":100},"52522","VILDAGLIPTIN TABLET ORAL 50 mg","قرص ویلداگلیپتین ۵۰ میلی‌گرم",[102],{"source":103,"section":104,"url":105},"darooyab-generic","G-3925\u002FVildagliptin","https:\u002F\u002Fwww.darooyab.ir\u002FG-3925\u002FVildagliptin",[107,110,112],{"kind":108,"url":109,"label":89},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BH02",{"kind":111,"url":105,"label":8},"darooyab",{"kind":113,"url":114,"label":115},"emc","https:\u002F\u002Fwww.medicines.org.uk\u002Femc\u002Fproduct\u002F6225\u002Fsmpc","UK Galvus SmPC",{"pregnancy":117,"lactation":126,"pediatric":133,"geriatric":141},{"level":118,"text":119,"quote":122,"refs":123},"caution",{"fa":120,"en":121},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","There are no adequate data from the use of vildagliptin in pregnant women.",[124],{"source":33,"section":125},"4.6",{"level":118,"text":127,"quote":130,"refs":131},{"fa":128,"en":129},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Animal studies have shown excretion of vildagliptin in milk.",[132],{"source":33,"section":125},{"level":134,"text":135,"quote":138,"refs":139},"not-established",{"fa":136,"en":137},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and efficacy of Galvus in children and adolescents (\u003C 18 years) have not been established.",[140],{"source":33,"section":34},{"level":142,"text":143,"quote":146,"refs":147},"ok",{"fa":144,"en":145},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","Elderly (≥ 65 years) No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2).",[148],{"source":33,"section":34},1792111471403]